MedTrace Logo

At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19

NCT04656691 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 139

Last updated 2022-03-18

Study results available
· View outcomes & findings →

Summary

This is an open-label, pragmatic, single-dose study using matched controls in participants with mild to moderate COVID-19. Participants will track for developing symptoms while at home and upon reporting of symptoms will test for COVID-19. If positive for COVID-19, a one-time at-home infusion of Bamlanivimab (LY3819253) will be provided by Optum Infusion. Participants will then track for 28 days to assess for any additional medical care needed or if hospitalization was required.

Conditions

  • Covid19

Interventions

DRUG

bamlanivimab

Participants that test positive for COVID-19 may be eligible to receive an in-home infusion of bamlanivimab by a registered nurse. This infusion will last approximately 1 hour followed by 1 hour of observation.

Sponsors & Collaborators

  • Eli Lilly and Company

    collaborator INDUSTRY

  • Optum, Inc.

    collaborator INDUSTRY

  • Daniel Griffin

    lead INDUSTRY

Principal Investigators

  • Dan Griffin, MD, PHD · ProHealth New York - UnitedHealth Group

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-04
Primary Completion
2021-04-18
Completion
2021-04-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04656691 on ClinicalTrials.gov